U.S. Dermatology Partners has been ranked the number one dermatology practice in the country by Castle Connolly’s 2025 Accolades.

Each year, Castle Connolly Accolades recognize health systems, hospitals, and physician practices that provide an outstanding level of high-quality healthcare through top-ranked Castle Connolly Top Doctor physicians. Castle Connolly Top Doctors represent the top 7% of practicing physicians in the U.S. and are selected by peer-to-peer nominations combined with a rigorous research process. This ensures only the most qualified physicians are included. Ninety U.S. Dermatology Partners physicians are recognized as 2025 Castle Connolly Top Doctors, resulting in the company’s superior rankings nationally and by state.

Health Technology Insights: Xsolis Partners with Beacon Health to Provide Gen AI Solution to Maximize Clinical Efficiencies

U.S. Dermatology Partners has earned the following 2025 Castle Connolly Accolades:

  • #1 Dermatology Practice in the Nation
  • #14 Private Practice Overall in the Nation
  • #1 Private Practice for Rising Stars, Most Top Doctors in the Nation
  • #1 Dermatology Practice in Arizona, Kansas, Maryland, and Texas
  • #1 Private Practice Overall in Kansas
  • #2 Private Practice Overall in Texas
  • #2 Dermatology Practice in Missouri
  • #5 Private Practice Overall in Arizona

Health Technology Insights: Physician Practice to Offer the Hybrid Choice Concierge Program

“Being recognized as Castle Connolly’s number one dermatology practice in the United States, in addition to receiving 10 other national and statewide accolades is an incredible honor,” said Paul Singh, CEO of U.S. Dermatology Partners. “These prestigious peer-nominated rankings reflect our team’s tremendous talent and dedication to providing the highest level of care to the communities we serve. We’re thankful for our patients and physician partners for their trust in U.S. Dermatology Partners and establishing our practice as a leader in our communities and nationwide.” 

Health Technology Insights: HOPE Therapeutics, and NRx Pharmaceuticals, Agreement $27 Million Funding

To participate in our interviews, please write to our HealthTech Media Room at news@intentamplify.com

Source – prnewswire